127 related articles for article (PubMed ID: 12660017)
1. DNA targeting of two new antitumour rebeccamycin derivatives.
Facompré M; Baldeyrou B; Bailly C; Anizon F; Marminon C; Prudhomme M; Colson P; Houssier C
Eur J Med Chem; 2002 Dec; 37(12):925-32. PubMed ID: 12660017
[TBL] [Abstract][Full Text] [Related]
2. Recognition of specific sequences in DNA by a topoisomerase I inhibitor derived from the antitumor drug rebeccamycin.
Bailly C; Colson P; Houssier C; Rodrigues-Pereira E; Prudhomme M; Waring MJ
Mol Pharmacol; 1998 Jan; 53(1):77-87. PubMed ID: 9443934
[TBL] [Abstract][Full Text] [Related]
3. Enhanced binding to DNA and topoisomerase I inhibition by an analog of the antitumor antibiotic rebeccamycin containing an amino sugar residue.
Bailly C; Qu X; Anizon F; Prudhomme M; Riou JF; Chaires JB
Mol Pharmacol; 1999 Feb; 55(2):377-85. PubMed ID: 9927631
[TBL] [Abstract][Full Text] [Related]
4. A DNA binding indolocarbazole disaccharide derivative remains highly cytotoxic without inhibiting topoisomerase I.
Qu X; Chaires JB; Ohkubo M; Yoshinari T; Nishimura S; Bailly C
Anticancer Drug Des; 1999 Oct; 14(5):433-42. PubMed ID: 10766298
[TBL] [Abstract][Full Text] [Related]
5. DNA cleavage by topoisomerase I in the presence of indolocarbazole derivatives of rebeccamycin.
Bailly C; Riou JF; Colson P; Houssier C; Rodrigues-Pereira E; Prudhomme M
Biochemistry; 1997 Apr; 36(13):3917-29. PubMed ID: 9092822
[TBL] [Abstract][Full Text] [Related]
6. Rebeccamycin analogues as anti-cancer agents.
Prudhomme M
Eur J Med Chem; 2003 Feb; 38(2):123-40. PubMed ID: 12620658
[TBL] [Abstract][Full Text] [Related]
7. Indolocarbazole glycosides in inactive conformations.
Facompré M; Carrasco C; Vezin H; Chisholm JD; Yoburn JC; Van Vranken DL; Bailly C
Chembiochem; 2003 May; 4(5):386-95. PubMed ID: 12740810
[TBL] [Abstract][Full Text] [Related]
8. Substitution at the F-ring N-imide of the indolocarbazole antitumor drug NB-506 increases the cytotoxicity, DNA binding, and topoisomerase I inhibition activities.
Bailly C; Qu X; Chaires JB; Colson P; Houssier C; Ohkubo M; Nishimura S; Yoshinari T
J Med Chem; 1999 Jul; 42(15):2927-35. PubMed ID: 10425102
[TBL] [Abstract][Full Text] [Related]
9. DNA binding and topoisomerase I poisoning activities of novel disaccharide indolocarbazoles.
Facompre M; Carrasco C; Colson P; Houssier C; Chisholm JD; Van Vranken DL; Bailly C
Mol Pharmacol; 2002 Nov; 62(5):1215-27. PubMed ID: 12391286
[TBL] [Abstract][Full Text] [Related]
10. Calories from carbohydrates: energetic contribution of the carbohydrate moiety of rebeccamycin to DNA binding and the effect of its orientation on topoisomerase I inhibition.
Bailly C; Qu X; Graves DE; Prudhomme M; Chaires JB
Chem Biol; 1999 May; 6(5):277-86. PubMed ID: 10322124
[TBL] [Abstract][Full Text] [Related]
11. Rebeccamycin analogues bearing amine substituents or other groups on the sugar moiety.
Anizon F; Moreau P; Sancelme M; Laine W; Bailly C; Prudhomme M
Bioorg Med Chem; 2003 Aug; 11(17):3709-22. PubMed ID: 12901916
[TBL] [Abstract][Full Text] [Related]
12. Rebeccamycin derivatives as dual DNA-damaging agents and potent checkpoint kinase 1 inhibitors.
Marminon C; Anizon F; Moreau P; Pfeiffer B; Pierré A; Golsteyn RM; Peixoto P; Hildebrand MP; David-Cordonnier MH; Lozach O; Meijer L; Prudhomme M
Mol Pharmacol; 2008 Dec; 74(6):1620-9. PubMed ID: 18768386
[TBL] [Abstract][Full Text] [Related]
13. Rebeccamycin analogues from indolo[2,3-c]carbazole.
Voldoire A; Sancelme M; Prudhomme M; Colson P; Houssier C; Bailly C; Léonce S; Lambel S
Bioorg Med Chem; 2001 Feb; 9(2):357-65. PubMed ID: 11249128
[TBL] [Abstract][Full Text] [Related]
14. Semi-synthesis, topoisomerase I and kinases inhibitory properties, and antiproliferative activities of new rebeccamycin derivatives.
Moreau P; Gaillard N; Marminon C; Anizon F; Dias N; Baldeyrou B; Bailly C; Pierré A; Hickman J; Pfeiffer B; Renard P; Prudhomme M
Bioorg Med Chem; 2003 Nov; 11(23):4871-9. PubMed ID: 14604648
[TBL] [Abstract][Full Text] [Related]
15. Recent developments of rebeccamycin analogues as topoisomerase I inhibitors and antitumor agents.
Prudhomme M
Curr Med Chem; 2000 Dec; 7(12):1189-212. PubMed ID: 11032967
[TBL] [Abstract][Full Text] [Related]
16. Syntheses and biological activities (topoisomerase inhibition and antitumor and antimicrobial properties) of rebeccamycin analogues bearing modified sugar moieties and substituted on the imide nitrogen with a methyl group.
Anizon F; Belin L; Moreau P; Sancelme M; Voldoire A; Prudhomme M; Ollier M; Sevère D; Riou JF; Bailly C; Fabbro D; Meyer T
J Med Chem; 1997 Oct; 40(21):3456-65. PubMed ID: 9341921
[TBL] [Abstract][Full Text] [Related]
17. Triple helix-forming oligonucleotides conjugated to indolocarbazole poisons direct topoisomerase I-mediated DNA cleavage to a specific site.
Arimondo PB; Bailly C; Boutorine AS; Moreau P; Prudhomme M; Sun JS; Garestier T; Hélène C
Bioconjug Chem; 2001; 12(4):501-9. PubMed ID: 11459453
[TBL] [Abstract][Full Text] [Related]
18. Syntheses and biological activities of rebeccamycin analogues with uncommon sugars.
Zhang G; Shen J; Cheng H; Zhu L; Fang L; Luo S; Muller MT; Lee GE; Wei L; Du Y; Sun D; Wang PG
J Med Chem; 2005 Apr; 48(7):2600-11. PubMed ID: 15801850
[TBL] [Abstract][Full Text] [Related]
19. Engineering biosynthetic pathways to generate antitumor indolocarbazole derivatives.
Sánchez C; Méndez C; Salas JA
J Ind Microbiol Biotechnol; 2006 Jul; 33(7):560-8. PubMed ID: 16491358
[TBL] [Abstract][Full Text] [Related]
20. Cytotoxicities of three rebeccamycin derivatives in the National Cancer Institute screening of 60 human tumor cell lines.
Moreau P; Holbeck S; Prudhomme M; Sausville EA
Anticancer Drugs; 2005 Feb; 16(2):145-50. PubMed ID: 15655411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
